Bayer’s heart failure drug bound for NHS on NICE recommendation
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Bayer’s non-steroidal heart failure drug, Kerendia (finerenone), for…
17 Jul 2026
FDA grants traditional approval to Novartis’ Fabhalta for IgAN
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy…
17 Jul 2026
MSD wins FDA approval for cholesterol pill to help plug Keytruda void
MSD (Merck & Co) has won US Food and Drug Administration (FDA) approval for its cholesterol-lowering pill, marking a significant milestone in the drugmaker’s push to reduce revenue reliance on…
17 Jul 2026
JCVI issues recommendation on adolescent MenB vaccination in UK
The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended a routine programme with the 4CMenB vaccine for adolescents. The Department of Health and Social Care (DHSC) will consider…
16 Jul 2026
UK commits to pharma IP protection in Swiss trade deal
The UK government has committed to maintaining its existing intellectual property (IP) framework for pharmaceuticals as part of a new trade deal with Switzerland. The agreement locks in place IP…
16 Jul 2026
Novo secures European approval for oral Wegovy to extend lead over Lilly
Novo Nordisk is continuing to maintain its advantage in the obesity pill race after winning European approval for oral Wegovy (semaglutide). The European Commission (EC) granted marketing authorisation to the…
16 Jul 2026
Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover
Following its high-profile dealmaking spree in the first portion of 2026, Eli Lilly has struck again – this time through a multi-billion-dollar acquisition of psychedelic biotech, AtaiBeckley. Through the deal,…